Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $865.27M |
| Gross Profit (TTM) | $806.85M |
| EBITDA | $-152.80M |
| Operating Margin | -5.18% |
| Return on Equity | -175.60% |
| Return on Assets | -13.70% |
| Revenue/Share (TTM) | $16.79 |
| Book Value | $2.00 |
| Price-to-Book | 68.35 |
| Price-to-Sales (TTM) | 7.89 |
| EV/Revenue | 8.22 |
| EV/EBITDA | -14.81 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 51.90% |
| Shares Outstanding | $52.60M |
| Float | $44.68M |
| % Insiders | 15.02% |
| % Institutions | 73.91% |
Volatility is currently expanding
Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
Third-quarter revenue grew 52% year over year to $260 million. Management expects Auvelity to reach $8 billion in peak annual revenue.
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat: Monday, November 9, 2026, at 11:30 a.m. ET in Boston, MA 8th Annual Wolfe Research Healthcare Conference Investor Meetings: Tuesday, November 10, 2026, in New York, NY 2026 Truist BioPharma Symposium Investor Meetings: Thursday, November 12, 2026, in New York, NY UBS Global Biopharma Conference 2026 Fireside Chat: Monday, November 16, 2026, at 11:20 a.m.
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
Axsome Therapeutics NASDAQ: AXSM reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's disease agitation.
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.94 per share a year ago.
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO ® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated Company to host conference call today at 8:00 AM Eastern Time NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2026 and provided a general business update. “Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate.
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AXSM and any ticker you trade — then tracks every position and per-strategy win rate.
